Cefpodoxime Proxetil for Oral Suspension Rx
Generic Name and Formulations:
Cefpodoxime proxetil 50mg/5mL, 100mg/5mL; for oral susp; lemon-creme flavor.
Various generic manufacturers
Indications for Cefpodoxime Proxetil for Oral Suspension:
Susceptible mild to moderate infections including acute otitis media, acute bacterial exacerbations of chronic bronchitis, acute maxillary sinusitis, pharyngitis/tonsillitis, acute community-acquired pneumonia, urinary tract, skin and skin structures; cervical, anorectal (females only) and urethral gonorrhea.
Take tabs with food. ≥13yrs: Pneumonia: 200mg every 12hrs for 14 days. Bronchitis, sinusitis: 200mg every 12hrs for 10 days. Pharyngitis/tonsillitis: 100mg every 12hrs for 5–10 days. Skin and skin structures: 400mg every 12hrs for 7–14 days. UTI: 100mg every 12hrs for 7 days. Uncomplicated gonorrhea: 200mg once as a single dose. Renal failure or hemodialysis: see full labeling.
Use susp. <2 months: not recommended. 2 months–12yrs: Acute otitis media: 5mg/kg (max 200mg) every 12hrs for 5 days. Pharyngitis/tonsillitis: 5mg/kg (max 100mg) every 12hrs for 5–10 days. Sinusitis: 5mg/kg (max 200mg) every 12hrs for 10 days.
Penicillin or other allergy. Labor & delivery. Pregnancy (Cat.B). Nursing mothers: not recommended.
Antacids, H2 antagonists, oral anticholinergics may decrease efficacy. Potentiated by probenecid. Avoid concomitant diuretics, other nephrotoxic drugs. May cause false (+) direct Coomb's test.
GI upset, abdominal pain, headache, rash, anaphylaxis.
Formerly known under the brand name Vantin.
Endocrinology Advisor Articles
- Efficacy and Safety of Alirocumab in Diabetes Mellitus
- Safety of DPP-IV Inhibitor, Cardiovascular Events After ACS in Type 2 Diabetes
- Sex Hormone Levels May Affect Postmenopausal Heart Disease Risk
- Effect of Fructose, Allulose on Postprandial Glucose Regulation in Type 2 Diabetes
- Transgender Youth Not Willing to Delay Hormone Therapy for Fertility Preservation
- Diabetes Treatments
- Metformin May Decrease Colorectal Cancer Risk Among Males With Diabetes
- SGLT2 Inhibitor, GLP-1 Receptor Agonist Combination Treatment for Type 2 Diabetes: Expert Insights
- Semaglutide May Induce Weight Loss in Type 2 Diabetes Despite BMI
- FDA Clears Omnipod DASH System for Diabetes Management
- Single Blood Sample Highly Predictive for Subsequent Diabetes Diagnosis
- Plasma Methylglyoxal Levels Associated With CVD, Mortality in Type 2 Diabetes
- Adjunctive Metformin for Insulin Resistance in T1D: A Clinical Perspective
- AMA: Federal Government Must Tackle Rising Insulin Prices
- Diabetes Medication Reconciliation May Reduce Risk of ED Visits